Solution

• Carcinogenicity assessment
• Data sharing
• Genotoxic impurity evaluation
• Impurity and degradant control
• In silico mutagenicity assessment
• Metabolite identification and analysis
• Nitrosamine impurity risk assessment
• Non-genotoxic impurity assessment
• Safety profiling in drug discovery
• Skin sensitisation assessment